Pharmacology & ToxicologybioRxivPreprint
Shifting KRAS hotspot mutations inhibition paradigm in colorectal cancer
A. R. Bras, A. Lopes, N. Mendes…·A. Preto
This study identifies a ruthenium compound, PMC79, that selectively inhibits KRAS mutations in colorectal cancer and enhances chemotherapy efficacy.
DOI 10.1101/2023.08.09.552513